Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merja H Voutilainen

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Neuroscience Letters|October 6, 2023
Feasibility of combining alpha-synuclein aggregation and 6-OHDA in embryonic midbrain culture for modeling dopamine neuron degenerationAastha Singh, Anne Panhelainen, Merja H Voutilainen
Frontiers in Cellular Neuroscience|July 26, 2021
MANF Is Neuroprotective in Early Stages of EAE, and Elevated in Spinal White Matter by Treatment With DexamethasoneJinhan Nam, Tapani K Koppinen, Merja H Voutilainen
FEBS Letters|October 10, 2015
Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's diseaseMerja H Voutilainen, Urmas Arumäe, Mikko Airavaara, et al.
Brain, Behavior, & Immunity - Health|March 2, 2026
Corrigendum to "Animal models of Huntington's disease. Pros and cons" [Brain, Behavior, Immunity Health 50 (2025) 101149Polina Stepanova, Ove Eriksson, Merja H Voutilainen, et al.
Parkinsonism & Related Disorders|September 20, 2011
WITHDRAWN: NeurorestorationMikko Airavaara, Merja H Voutilainen, Yun Wang, et al.
Brain, Behavior, & Immunity - Health|December 24, 2025
Animal models of Huntington's disease. Pros and consPolina Stepanova, Merja H Voutilainen, Ove Eriksson, et al.
Parkinsonism & Related Disorders|December 15, 2011
NeurorestorationMikko Airavaara, Merja H Voutilainen, Yun Wang, et al.
Genes|February 18, 2017
AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease ModelsKatrina Albert, Merja H Voutilainen, Andrii Domanskyi, et al.
Scientific Reports|July 17, 2024
Delivery of CDNF by AAV-mediated gene transfer protects dopamine neurons and regulates ER stress and inflammation in an acute MPTP mouse model of Parkinson's diseaseJinhan Nam, Christopher T Richie, Brandon K Harvey, et al.
The European Journal of Neuroscience|December 10, 2023
Combining fibril-induced alpha-synuclein aggregation and 6-hydroxydopamine in a mouse model of Parkinson's disease and the effect of cerebral dopamine neurotrophic factor on the induced neurodegenerationAastha Singh, Anne Panhelainen, Saku Reunanen, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Neuroscience Letters|October 6, 2023
Feasibility of combining alpha-synuclein aggregation and 6-OHDA in embryonic midbrain culture for modeling dopamine neuron degenerationAastha Singh, Anne Panhelainen, Merja H Voutilainen
Frontiers in Cellular Neuroscience|July 26, 2021
MANF Is Neuroprotective in Early Stages of EAE, and Elevated in Spinal White Matter by Treatment With DexamethasoneJinhan Nam, Tapani K Koppinen, Merja H Voutilainen
FEBS Letters|October 10, 2015
Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's diseaseMerja H Voutilainen, Urmas Arumäe, Mikko Airavaara, et al.
Brain, Behavior, & Immunity - Health|March 2, 2026
Corrigendum to "Animal models of Huntington's disease. Pros and cons" [Brain, Behavior, Immunity Health 50 (2025) 101149Polina Stepanova, Ove Eriksson, Merja H Voutilainen, et al.
Parkinsonism & Related Disorders|September 20, 2011
WITHDRAWN: NeurorestorationMikko Airavaara, Merja H Voutilainen, Yun Wang, et al.
Brain, Behavior, & Immunity - Health|December 24, 2025
Animal models of Huntington's disease. Pros and consPolina Stepanova, Merja H Voutilainen, Ove Eriksson, et al.
Parkinsonism & Related Disorders|December 15, 2011
NeurorestorationMikko Airavaara, Merja H Voutilainen, Yun Wang, et al.
Genes|February 18, 2017
AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease ModelsKatrina Albert, Merja H Voutilainen, Andrii Domanskyi, et al.
Scientific Reports|July 17, 2024
Delivery of CDNF by AAV-mediated gene transfer protects dopamine neurons and regulates ER stress and inflammation in an acute MPTP mouse model of Parkinson's diseaseJinhan Nam, Christopher T Richie, Brandon K Harvey, et al.
The European Journal of Neuroscience|December 10, 2023
Combining fibril-induced alpha-synuclein aggregation and 6-hydroxydopamine in a mouse model of Parkinson's disease and the effect of cerebral dopamine neurotrophic factor on the induced neurodegenerationAastha Singh, Anne Panhelainen, Saku Reunanen, et al.
Pageof 5